This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips
by Zacks Equity Research
Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.
EYE vs. PODD: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. PODD: Which Stock Is the Better Value Option?
InMode (INMD) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is likely to register growth in Q3, backed by strong consumable and service revenues and ongoing global expansion.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.
Labcorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.
IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.
What's in Store for Option Care Health (OPCH) in Q3 Earnings?
by Zacks Equity Research
Option Care Health's (OPCH) Q3 results are likely to be driven by sustained strong utilization.
Insulet (PODD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and latest launches.
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
by Zacks Equity Research
Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.
Down -20.51% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.
Down -21.98% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround
by Zacks Equity Research
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Insulet (PODD) Loses -24.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
5 Medical Product Stocks to Buy Amid Industry Recovery
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) third-quarter 2023 results are likely to reflect solid underlying base business organic sales growth.
Down -17.48% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Looking for Earnings Beat? 5 Top-Ranked Stocks to Play
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap NVIDIA (NVDA), Lamb Weston (LW), Insulet (PODD), Asure Software (ASUR) and Palo Alto Networks (PANW).